Literature DB >> 9546815

Cytokines in the evolution of Graves' ophthalmopathy.

N Natt1, R S Bahn.   

Abstract

Infiltration of the retroocular space by inflammatory cells and the accumulation of glycosaminoglycans are histological characteristics of Graves' ophthalmopathy. Various cytokines, released by infiltrating immunocompetent cells and resident connective tissue cells, play a pivotal role in the evolution of this disease. The predominant cytokines secreted by orbital T cells during the course of the disease may govern the activity and stage of the local autoimmune process. Cytokine effects of potential relevance to the pathogenesis of Graves' ophthalmopathy include their ability to stimulate orbital fibroblasts to proliferate and secrete excess quantities of glycosaminoglycans. The edema associated with these hydrophilic macromolecules is directly responsible for many of the characteristic clinical features of the disease. In addition, certain cytokines induce or enhance the expression on orbital fibroblasts of immunomodulatory proteins. We review current evidence supporting the notion that cytokines are central to the development and evolution of Graves' ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9546815     DOI: 10.3109/08916939709003857

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  11 in total

1.  Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression.

Authors:  A K Eckstein; B Quadbeck; S Tews; K Mann; C Krüger; C H Mohr; K-P Steuhl; J Esser; R K Gieseler
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves' disease.

Authors:  Omid Khalilzadeh; Mehdi Anvari; Fatemeh Momen-Heravi; Alireza Esteghamati; Armin Rashidi; Mahdi Mahmoudi; Behrouz Nikbin; Aliakbar Amirzargar
Journal:  Clin Exp Med       Date:  2009-10-31       Impact factor: 3.984

Review 3.  Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy.

Authors:  Meritxell Arenas; Sebastià Sabater; Pedro Lara Jiménez; Àngels Rovirosa; Albert Biete; Victoria Linares; Montse Belles; Julià Panés
Journal:  Rep Pract Oncol Radiother       Date:  2016-03-04

4.  Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy.

Authors:  Delu Song; Renyan Wang; Yong Zhong; Weiye Li; Hui Li; Fangtian Dong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-09       Impact factor: 3.117

5.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

Review 6.  Thyroid dysfunction: an autoimmune aspect.

Authors:  Farah Aziz Khan; Noura Al-Jameil; Mohammad Fareed Khan; May Al-Rashid; Hajera Tabassum
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  Graves' ophthalmopathy: a review of immunogenetics.

Authors:  Omid Khalilzadeh; Sina Noshad; Armin Rashidi; Aliakbar Amirzargar
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

8.  Tocilizumab for thyroid eye disease.

Authors:  Shirin Hamed Azzam; Swan Kang; Mario Salvi; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27

Review 9.  Genetic Associations of Interleukin-related Genes with Graves' Ophthalmopathy: a Systematic Review and Meta-analysis.

Authors:  Kah Hie Wong; Shi Song Rong; Kelvin K L Chong; Alvin L Young; Chi Pui Pang; Li Jia Chen
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

10.  Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy.

Authors:  Edina Kishazi; Marianne Dor; Simone Eperon; Aurélie Oberic; Natacha Turck; Mehrad Hamedani
Journal:  Sci Rep       Date:  2018-07-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.